ACTA1 and systemic sclerosis: Another study indicated that CTLA4-Ig (Abatacept) significantly downregulated the expression of key fibrotic markers (such as αSMA and COL I) in circulating fibrocytes from SSc patients in vitro, with no significant effect on fibrocytes from healthy controls [92].